NephroPlus Files DRHP with Sebi for Rs 2000 Crore IPO

Hyderabad: Nephrocare Health Services Limited, known as NephroPlus, has taken a significant step towards its initial public offering (IPO) by filing a draft red herring prospectus (DRHP) with the Securities & Exchange Board of India (Sebi). The IPO is estimated to be around Rs 2000 crore, marking a pivotal moment for Asia's largest dialysis services provider.

IPO Details and Strategic Goals

The company plans to raise Rs 353.4 crore through a fresh issue of shares and an offer for sale (OFS) of over 1.27 crore shares by selling shareholders. The proceeds will be utilized for opening new dialysis clinics in India, repaying borrowings, and for general corporate purposes. NephroPlus may also consider a pre-IPO placement of up to Rs 70.6 crore.

Global Footprint and Financial Performance

With operations in 21 states and 4 Union territories in India, and a growing presence in the Philippines, Uzbekistan, Nepal, and Saudi Arabia, NephroPlus serves over 33,000 patients annually. The company reported a profit after tax of Rs 67 crore on revenue of nearly Rs 756 crore in the financial year 2024-25.

Investor Participation

The OFS includes participation from prominent investors such as Investcorp Private Equity Fund II, Healthcare Parent Limited, and International Finance Corporation, among others. This diverse investor base underscores the confidence in NephroPlus's business model and growth prospects.